Article Text

This article has a correction. Please see:

other Versions

PDF
The preterm infant with thrombosis
  1. Rukhmi Bhat1,
  2. Paul Monagle2
  1. 1Hematology/Oncology/Stem cell transplant, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
  2. 2Department of Clinical Haematology, Department of Paediatrics, Royal Children's Hospital, University of Melbourne, Melbourne, Australia
  1. Correspondence to Rukhmi Bhat, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Hematology/Oncology/Stem cell transplant, Chicago, Illinois 60614, USA; rbhat{at}childrensmemorial.org

Abstract

In paediatrics, sick preterm infants are at highest risk of developing thrombotic complications. Haemostasis is in a fine balance in the neonatal period, despite age-related differences in coagulation proteins. However, both inherited and acquired risk factors can disrupt this balance and can lead to thrombosis. Important risk factors are sepsis, asphyxia, dehydration, central venous lines and inherited and acquired thrombophilia. Among various treatment modalities, anticoagulation is primarily used in the management of thrombosis. Different agents, dosages and durations of treatment in this age group are extrapolated from adult data. The article reviews the epidemiology, pathophysiology, risk factors, diagnosis and treatment of thrombotic disorders in preterm infants.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health